Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety. (PubMed, Drug Des Devel Ther) - Sep 15, 2026 - "Peficitinib has the most mature evidence base, including Phase 3 efficacy, radiographic protection, long-term extension data, and pooled safety analyses. Ivarmacitinib has phase 3 and exploratory MRI data, whereas the phase 3 trial of TLL-018 has reached primary completion, with sponsor-reported topline findings available but complete results not yet published. CPL409116/CPL'116 remains supported by limited Phase 2 evidence. Decernotinib represents an informative historical proof-of-concept programme. Overall, no emerging agent has yet demonstrated a reproducible advantage over established JAK inhibitors in sustained remission, structural preservation, difficult-to-treat disease, or overall benefit-risk balance. Future development should prioritise active comparators, prespecified structural outcomes, prolonged safety assessment, and prospectively validated treatment-specific biomarkers."
Journal • Review • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
|
|
Francesco Caso; Francesco Maione; Luisa Costa; Piero Ruscitti; Roberto Giacomelli
|